The University of Southampton
University of Southampton Institutional Repository

Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design

Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design
Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design

Background: Current ESC guidelines recommend the use of intra-coronary pressure guidewires for functional assessment of intermediate-grade coronary stenoses. Angiography-derived quantitative flow ratio (QFR) is a novel method of assessing these stenoses, and guiding percutaneous coronary intervention (PCI). Methods/Design: The PIONEER IV trial is a prospective, all-comers, multi-center trial, which will randomize 2,540 patients in a 1:1 ratio to PCI guided by angiography-derived physiology or usual care, with unrestricted use in both arms of the Healing-Targeted Supreme sirolimus-eluting stent (HT Supreme). The stent's fast, biologically healthy, and robust endothelial coverage allows for short dual-antiplatelet therapy (DAPT); hence the antiplatelet regimen of choice is 1-month DAPT, followed by ticagrelor monotherapy. In the angiography-derived physiology guided arm, lesions will be functionally assessed using on-line QFR, with stenting indicated in lesions with a QFR ≤0.80. Post-stenting, QFR will be repeated in the stented vessel(s), with post-dilatation or additional stenting recommended if the QFR<0.91 distal to the stent, or if the delta QFR (across the stent) is >0.05. Usual care PCI is performed according to standard clinical practice. The primary endpoint is a non–inferiority comparison of the patient-oriented composite endpoint (POCE) of all-cause death, any stroke, any myocardial infarction, or any clinically, and physiologically driven revascularization with a non–inferiority risk-difference margin of 3.2%, at 1-year post-procedure. Clinical follow-up will be up to 3 years. The PIONEER IV trial aims to demonstrate non–inferiority of QFR-guided PCI to usual care PCI with respect to POCE at 1-year in patients treated with HT Supreme stents and ticagrelor monotherapy. Clinical Trial Registration: ClinicalTrials.gov Unique Identifier: NCT04923191 Classifications: Interventional Cardiology

Coronary Angiography, Coronary Artery Disease/therapy, Drug-Eluting Stents, Humans, Percutaneous Coronary Intervention/methods, Prospective Studies, Stents, Ticagrelor/therapeutic use, Treatment Outcome
0002-8703
32-43
Hara, Hironori
05ad55ae-1f1d-466a-98e6-c47c58c8a070
Serruys, Patrick W.
98dfd61b-78fb-4f77-9995-7d9959332961
O'Leary, Neil
a2b9c6fd-6871-4eeb-be6d-356f45436d36
Gao, Chao
249a2c6e-cf9a-4463-bd78-0f2ad7a17a3a
Murray, Alicia
4b2d75f0-ac23-4822-a91d-a630679c7071
Breslin, Elaine
86c44a97-0b07-4d7d-bba7-d5b10d8ac774
Garg, Scot
f504ab90-e0d5-4567-9c49-0c6cf2137c74
Bureau, Christophe
3c6056d1-6e08-4f3b-b451-539f5aa234e0
Reiber, Johan HC
46a7a0a5-b007-4c23-9b3b-ca7e14bcb829
Barbato, Emanuele
50106486-a9cd-4c08-9ee7-74d049a9356d
Aminian, Adel
a7af9afb-d528-45cb-a61d-ecee14541243
Janssens, Luc
43a3def3-9012-420d-b5d7-367b7d94e9d6
Rosseel, Liesbeth
7bbf7b2b-b0f0-4c6b-aa2e-b703274a0a13
Benit, Edouard
8df377c5-4b71-437d-b2b5-d933ce0fe4a8
Campo, Gianluca
56959271-26a6-44d1-9aed-feedaf093b96
Guiducci, Vincenzo
932ac294-31c1-4f4c-8104-6ed50ed71cae
Casella, Gianni
d2fb56d9-cdd1-4103-8e14-377aa6d58282
Santarelli, Andrea
37c01e06-2ba5-4ebc-8bb9-495f46266cf2
Franzè, Alfonso
db7ad58b-5651-4a58-8414-8274e834b356
Diaz, Victor Alfonso Jimenez
cf2a24e4-fc94-47c8-928e-dc9699e316a3
Iñiguez, Andrés
0e6df809-f9ea-4c9e-bbd3-935777f0988e
Brugaletta, Salvatore
956be673-43db-4f33-a073-39dd56b5122f
Sabate, Manel
bde81ec6-7678-4971-bfd7-0147edfddee9
Amat-Santos, Ignacio J.
52f2aa1e-529d-47f1-b015-b307df18bc99
Amoroso, Giovanni
96681fd7-5194-4c73-b439-0e0c31703b40
Wykrzykowska, Joanna
7f1370a3-8611-4974-9ee6-762884244eb0
von Birgelen, Clemens
4e767009-460f-4acc-89fc-4c6273e165a8
Somi, Samer
6d54521e-95ff-4349-99a4-b58f98bcfcff
Liu, Tommy
35b86b40-f0e7-47e4-a5f0-3a02d322928a
Hofma, Sjoerd H.
7da72d95-e69f-4831-8f68-2f112f273f1a
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Trillo, Ramiro
0f9fabe4-cc53-45b8-9a36-21cba15ae399
Ocaranza, Raymundo
8d005bd1-4d1b-45fe-a038-c2ed07cacac5
Mathur, Anthony
eb09e07f-799e-4f7c-9dc9-40a6df249398
Smits, Pieter C.
6753fe48-844c-4707-90a7-c7a55e04c0f0
Escaned, Javier
69f3a60d-03f9-4763-bec0-80b02344367f
Baumbach, Andreas
c5cc2c9b-73d8-402e-8aaa-8b856da9f7f3
Wijns, William
e3677790-8809-4faf-ba5c-f9efb1a578d5
Sharif, Faisal
af411836-417d-4394-b913-b4b09002e66f
Onuma, Yoshinobu
3bae88ea-1afa-43b2-bbd0-a68d72d78662
PIONEER IV trial investigator
Hara, Hironori
05ad55ae-1f1d-466a-98e6-c47c58c8a070
Serruys, Patrick W.
98dfd61b-78fb-4f77-9995-7d9959332961
O'Leary, Neil
a2b9c6fd-6871-4eeb-be6d-356f45436d36
Gao, Chao
249a2c6e-cf9a-4463-bd78-0f2ad7a17a3a
Murray, Alicia
4b2d75f0-ac23-4822-a91d-a630679c7071
Breslin, Elaine
86c44a97-0b07-4d7d-bba7-d5b10d8ac774
Garg, Scot
f504ab90-e0d5-4567-9c49-0c6cf2137c74
Bureau, Christophe
3c6056d1-6e08-4f3b-b451-539f5aa234e0
Reiber, Johan HC
46a7a0a5-b007-4c23-9b3b-ca7e14bcb829
Barbato, Emanuele
50106486-a9cd-4c08-9ee7-74d049a9356d
Aminian, Adel
a7af9afb-d528-45cb-a61d-ecee14541243
Janssens, Luc
43a3def3-9012-420d-b5d7-367b7d94e9d6
Rosseel, Liesbeth
7bbf7b2b-b0f0-4c6b-aa2e-b703274a0a13
Benit, Edouard
8df377c5-4b71-437d-b2b5-d933ce0fe4a8
Campo, Gianluca
56959271-26a6-44d1-9aed-feedaf093b96
Guiducci, Vincenzo
932ac294-31c1-4f4c-8104-6ed50ed71cae
Casella, Gianni
d2fb56d9-cdd1-4103-8e14-377aa6d58282
Santarelli, Andrea
37c01e06-2ba5-4ebc-8bb9-495f46266cf2
Franzè, Alfonso
db7ad58b-5651-4a58-8414-8274e834b356
Diaz, Victor Alfonso Jimenez
cf2a24e4-fc94-47c8-928e-dc9699e316a3
Iñiguez, Andrés
0e6df809-f9ea-4c9e-bbd3-935777f0988e
Brugaletta, Salvatore
956be673-43db-4f33-a073-39dd56b5122f
Sabate, Manel
bde81ec6-7678-4971-bfd7-0147edfddee9
Amat-Santos, Ignacio J.
52f2aa1e-529d-47f1-b015-b307df18bc99
Amoroso, Giovanni
96681fd7-5194-4c73-b439-0e0c31703b40
Wykrzykowska, Joanna
7f1370a3-8611-4974-9ee6-762884244eb0
von Birgelen, Clemens
4e767009-460f-4acc-89fc-4c6273e165a8
Somi, Samer
6d54521e-95ff-4349-99a4-b58f98bcfcff
Liu, Tommy
35b86b40-f0e7-47e4-a5f0-3a02d322928a
Hofma, Sjoerd H.
7da72d95-e69f-4831-8f68-2f112f273f1a
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Trillo, Ramiro
0f9fabe4-cc53-45b8-9a36-21cba15ae399
Ocaranza, Raymundo
8d005bd1-4d1b-45fe-a038-c2ed07cacac5
Mathur, Anthony
eb09e07f-799e-4f7c-9dc9-40a6df249398
Smits, Pieter C.
6753fe48-844c-4707-90a7-c7a55e04c0f0
Escaned, Javier
69f3a60d-03f9-4763-bec0-80b02344367f
Baumbach, Andreas
c5cc2c9b-73d8-402e-8aaa-8b856da9f7f3
Wijns, William
e3677790-8809-4faf-ba5c-f9efb1a578d5
Sharif, Faisal
af411836-417d-4394-b913-b4b09002e66f
Onuma, Yoshinobu
3bae88ea-1afa-43b2-bbd0-a68d72d78662

Hara, Hironori, Serruys, Patrick W., O'Leary, Neil, Gao, Chao, Murray, Alicia and Breslin, Elaine , PIONEER IV trial investigator (2022) Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. American Heart Journal, 246, 32-43. (doi:10.1016/j.ahj.2021.12.018).

Record type: Article

Abstract

Background: Current ESC guidelines recommend the use of intra-coronary pressure guidewires for functional assessment of intermediate-grade coronary stenoses. Angiography-derived quantitative flow ratio (QFR) is a novel method of assessing these stenoses, and guiding percutaneous coronary intervention (PCI). Methods/Design: The PIONEER IV trial is a prospective, all-comers, multi-center trial, which will randomize 2,540 patients in a 1:1 ratio to PCI guided by angiography-derived physiology or usual care, with unrestricted use in both arms of the Healing-Targeted Supreme sirolimus-eluting stent (HT Supreme). The stent's fast, biologically healthy, and robust endothelial coverage allows for short dual-antiplatelet therapy (DAPT); hence the antiplatelet regimen of choice is 1-month DAPT, followed by ticagrelor monotherapy. In the angiography-derived physiology guided arm, lesions will be functionally assessed using on-line QFR, with stenting indicated in lesions with a QFR ≤0.80. Post-stenting, QFR will be repeated in the stented vessel(s), with post-dilatation or additional stenting recommended if the QFR<0.91 distal to the stent, or if the delta QFR (across the stent) is >0.05. Usual care PCI is performed according to standard clinical practice. The primary endpoint is a non–inferiority comparison of the patient-oriented composite endpoint (POCE) of all-cause death, any stroke, any myocardial infarction, or any clinically, and physiologically driven revascularization with a non–inferiority risk-difference margin of 3.2%, at 1-year post-procedure. Clinical follow-up will be up to 3 years. The PIONEER IV trial aims to demonstrate non–inferiority of QFR-guided PCI to usual care PCI with respect to POCE at 1-year in patients treated with HT Supreme stents and ticagrelor monotherapy. Clinical Trial Registration: ClinicalTrials.gov Unique Identifier: NCT04923191 Classifications: Interventional Cardiology

Text
PIONEER IV_designpaper 30Dec2021 - Accepted Manuscript
Download (14MB)

More information

Accepted/In Press date: 30 December 2021
e-pub ahead of print date: 3 January 2022
Published date: April 2022
Keywords: Coronary Angiography, Coronary Artery Disease/therapy, Drug-Eluting Stents, Humans, Percutaneous Coronary Intervention/methods, Prospective Studies, Stents, Ticagrelor/therapeutic use, Treatment Outcome

Identifiers

Local EPrints ID: 456502
URI: http://eprints.soton.ac.uk/id/eprint/456502
ISSN: 0002-8703
PURE UUID: f907df6f-cfd4-4248-b5a6-72bd9cd6a539
ORCID for Nick Curzen: ORCID iD orcid.org/0000-0001-9651-7829

Catalogue record

Date deposited: 04 May 2022 16:38
Last modified: 18 Mar 2024 05:29

Export record

Altmetrics

Contributors

Author: Hironori Hara
Author: Patrick W. Serruys
Author: Neil O'Leary
Author: Chao Gao
Author: Alicia Murray
Author: Elaine Breslin
Author: Scot Garg
Author: Christophe Bureau
Author: Johan HC Reiber
Author: Emanuele Barbato
Author: Adel Aminian
Author: Luc Janssens
Author: Liesbeth Rosseel
Author: Edouard Benit
Author: Gianluca Campo
Author: Vincenzo Guiducci
Author: Gianni Casella
Author: Andrea Santarelli
Author: Alfonso Franzè
Author: Victor Alfonso Jimenez Diaz
Author: Andrés Iñiguez
Author: Salvatore Brugaletta
Author: Manel Sabate
Author: Ignacio J. Amat-Santos
Author: Giovanni Amoroso
Author: Joanna Wykrzykowska
Author: Clemens von Birgelen
Author: Samer Somi
Author: Tommy Liu
Author: Sjoerd H. Hofma
Author: Nick Curzen ORCID iD
Author: Ramiro Trillo
Author: Raymundo Ocaranza
Author: Anthony Mathur
Author: Pieter C. Smits
Author: Javier Escaned
Author: Andreas Baumbach
Author: William Wijns
Author: Faisal Sharif
Author: Yoshinobu Onuma
Corporate Author: PIONEER IV trial investigator

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×